University of Texas: Why Some Cancers May Respond Poorly to Key Drugs Discovered
September 23, 2020
September 23, 2020
AUSTIN, Texas, Sept. 23 (TNSJou) -- The University of Texas issued the following news release on Sept. 22:
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop - and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University in South Korea have identified a driver of the drug resistance that can make a life or death difference for patients with . . .
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop - and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University in South Korea have identified a driver of the drug resistance that can make a life or death difference for patients with . . .